SDI selected for third consecutive time as key monoclonal antibody provider

SDI (Strategic Diagnostics Inc., NASDAQ:SDIX), a leading provider of biotechnology-based products and services for a broad range of life science, food safety, and industrial applications, today announced it has been selected again by Science Applications International Corporation - Frederick (SAIC-F) to develop monoclonal antibodies for the National Cancer Institute’s “Clinical Proteomic Technologies for Cancer” initiative (CPTC: http://proteomics.cancer.gov). The SDI monoclonal antibodies will serve as reference reagents for the scientific cancer community.

SDI was selected for a third consecutive time as the key monoclonal antibody provider. The selection was based on SDI’s life sciences and antibody expertise, large-scale capacity, standardized processes, and fully-integrated quality management systems. The National Cancer Institute’s CPTC will extensively characterize these reagents consistent with their mission to make available high-quality reagents with baseline data to research scientists.

CPTC’s goal is to accelerate discovery and clinical research in cancer, using an integrated approach that assesses and optimizes proteomic technology measurement capabilities and develops universally accepted metrics to identify and minimize experimental variability from run-to-run, instrument-to-instrument, and lab-to-lab. CPTC aims to achieve this goal by optimizing existing platforms; developing innovative proteomic technologies and computational tools; and developing community reagents and resources. Its Proteomic Reagents & Resources component includes SOPs, data, proteins, and well-characterized, high-quality antibodies, whose performance characteristics will be observed at the Antibody Characterization Laboratory at NCI-Frederick (NCI-F), part of NCI-F’s Advanced Technology Program.

Commenting on the agreement, Mr. Fran DiNuzzo, SDI’s President and CEO, said, “SDI is proud to be a key supplier to this important large-scale cancer research initiative. Being selected for a third consecutive year by SAIC-F underscores our belief that SDI’s expertise, quality, infrastructure, and capacity position us as a premier supplier of comprehensive antibody services. Moreover, as the study of proteins continues to increase in importance to the research community, and antibodies continue to be the most widely-used tools for understanding the molecular dynamics underlying disease, we anticipate a continued demand for SDI products and services.”